The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics
Open accessAbstract
Lysosomal storage diseases (LSDs) are a group of genetic disorders due to defects in any aspect of lysosomal biology. During the past two decades, different approaches have been introduced for the treatment of these conditions. Among them, enzyme replacement therapy (ERT) represented a major advance and is used successfully in the treatment of some of these disorders. However, ERT has limitations such as insufficient biodistribution of recombinant enzymes and high costs. An emerging strategy for the treatment of LSDs is pharmacological chaperone therapy (PCT), based on the use of chaperone molecules that assist the folding of mutated enzymes and improve their stability and lysosomal trafficking. After proof-of-concept studies, PCT is now being translated into clinical applications for Fabry, Gaucher and Pompe disease. This approach, however, can only be applied to patients carrying chaperone-responsive mutations. The recent demonstration of a synergistic effect of chaperones and ERT expands the applications of PCT and prompts a re-evaluation of their therapeutic use and potential. This review discusses the strengths and drawbacks of the potential therapies available for LSDs and proposes that future research should be directed towards the development of treatment protocols based on the combination of different therapies to improve the clinical outcome of LSD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of lysosomal storage disorders
Meikle, P. J. (1999) · JAMA · doi:10.1001/jama.281.3.249 · Cited by 2,197
Quality control in the endoplasmic reticulum
Ellgaard, L., & Helenius, A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1052 · Cited by 2,126
Barton, N. W., Brady, R. O., Dambrosia, J. M., Di Bisceglie, A. M., Doppelt, S. H., Hill, S. C., Mankin, H. J., Murray, G. J., Parker, R. I., Argoff, C. E., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199105233242104 · Cited by 1,252
Biological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
The cell biology of lysosomal storage disorders
Futerman, A. H., & van Meer, G. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1423 · Cited by 796
van der Ploeg, A. T., & Reuser, A. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61555-x · Cited by 756
Fan, J.-Q., Ishii, S., Asano, N., & Suzuki, Y. (1999) · Nature Medicine · doi:10.1038/4801 · Cited by 614
Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study
Patterson, M. C., Vecchio, D., Prady, H., Abel, L., & Wraith, J. E. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70194-1 · Cited by 608
Lysosomal disorders: From storage to cellular damage
Ballabio, A., & Gieselmann, V. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.12.001 · Cited by 571
Worgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402
Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases
Mu, T.-W., Ong, D. S. T., Wang, Y.-J., Balch, W. E., Yates, J. R., Segatori, L., & Kelly, J. W. (2008) · Cell · doi:10.1016/j.cell.2008.06.037 · Cited by 359
Analysis and Classification of 304 Mutant Alleles in Patients with Type 1 and Type 3 Gaucher Disease
Koprivica, V., Stone, D. L., Park, J. K., Callahan, M., Frisch, A., Cohen, I. J., Tayebi, N., & Sidransky, E. (2000) · The American Journal of Human Genetics · doi:10.1086/302925 · Cited by 334
Frustaci, A., Chimenti, C., Ricci, R., Natale, L., Russo, M. A., Pieroni, M., Eng, C. M., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450104 · Cited by 332
Gene therapy for lysosomal storage diseases
Sands, M. S., & Davidson, B. L. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.006 · Cited by 285
Chemical chaperone therapy for brain pathology in G M1 -gangliosidosis
Matsuda, J., Suzuki, O., Oshima, A., Yamamoto, Y., Noguchi, A., Takimoto, K., Itoh, M., Matsuzaki, Y., Yasuda, Y., Ogawa, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536657100 · Cited by 262
Enzyme Replacement for Lysosomal Diseases
Brady, R. O. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.110104.115650 · Cited by 254
Pharmacologic Chaperones as a Potential Treatment for X-Linked Nephrogenic Diabetes Insipidus
Bernier, V., Morello, J.-P., Zarruk, A., Debrand, N., Salahpour, A., Lonergan, M., Arthus, M.-F. C., Laperrière, A., Brouard, R., Bouvier, M., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005080854 · Cited by 248
Structure of acid β-glucosidase with pharmacological chaperone provides insight into Gaucher disease
Lieberman, R. L., Wustman, B. A., Huertas, P., Powe, A. C., Pine, C. W., Khanna, R., Schlossmacher, M. G., Ringe, D., & Petsko, G. A. (2007) · Nature Chemical Biology · doi:10.1038/nchembio850 · Cited by 245
Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses
Butters, T. D., Dwek, R. A., & Platt, F. M. (2005) · Glycobiology · doi:10.1093/glycob/cwi076 · Cited by 218
Tropak, M. B., Reid, S. P., Guiral, M., Withers, S. G., & Mahuran, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308523200 · Cited by 197
Autophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe Disease
Fukuda, T., Ahearn, M., Roberts, A., Mattaliano, R. J., Zaal, K., Ralston, E., Plotz, P. H., & Raben, N. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.08.009 · Cited by 190
Gaucher Disease-Associated Glucocerebrosidases Show Mutation-Dependent Chemical Chaperoning Profiles
Sawkar, A. R., Adamski-Werner, S. L., Cheng, W.-C., Wong, C.-H., Beutler, E., Zimmer, K.-P., & Kelly, J. W. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.09.007 · Cited by 183
Zhu, Y., Jiang, J.-L., Gumlaw, N. K., Zhang, J., Bercury, S. D., Ziegler, R. J., Lee, K., Kudo, M., Canfield, W. M., Edmunds, T., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.37 · Cited by 177
Piotrowska, E., Jakóbkiewicz-Banecka, J., Barańska, S., Tylki-Szymańska, A., Czartoryska, B., Węgrzyn, A., & Węgrzyn, G. (2006) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201623 · Cited by 175
Benjamin, E. R., Flanagan, J. J., Schilling, A., Chang, H. H., Agarwal, L., Katz, E., Wu, X., Pine, C., Wustman, B., Desnick, R. J., et al. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1077-0 · Cited by 173
Pyrimethamine as a Potential Pharmacological Chaperone for Late-onset Forms of GM2 Gangliosidosis
Maegawa, G. H. B., Tropak, M., Buttner, J., Stockley, T., Kok, F., Clarke, J. T. R., & Mahuran, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609304200 · Cited by 171
Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs
Arakawa, T., Ejima, D., Kita, Y., & Tsumoto, K. (2006) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2006.08.012 · Cited by 166
Pey, A. L., Ying, M., Cremades, N., Velazquez-Campoy, A., Scherer, T., Thöny, B., Sancho, J., & Martinez, A. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34355 · Cited by 164
Platt, F. M., & Jeyakumar, M. (2008) · Acta Paediatrica · doi:10.1111/j.1651-2227.2008.00656.x · Cited by 157
Porto, C., Cardone, M., Fontana, F., Rossi, B., Tuzzi, M. R., Tarallo, A., Barone, M. V., Andria, G., & Parenti, G. (2009) · Molecular Therapy · doi:10.1038/mt.2009.53 · Cited by 153
Self-citationRegulation of Aquaporin-2 Trafficking
Nedvetsky, P. I., Tamma, G., Beulshausen, S., Valenti, G., Rosenthal, W., & Klußmann, E. (2008) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-79885-9_6 · Cited by 152
Lieberman, R. L., D’Aquino, J. A., Ringe, D., & Petsko, G. A. (2009) · Biochemistry · doi:10.1021/bi9002265 · Cited by 150
Pastores, G. M., Barnett, N. L., & Kolodny, E. H. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.08.004 · Cited by 147
Zheng, W., Padia, J. K., Urban, D. J., Jadhav, A., Göker-Alpan, Ö., Simeonov, A. M., Goldin, E., Auld, D. S., LaMarca, M. E., Inglese, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705637104 · Cited by 137
Muñoz-Rojas, M.-V., Vieira, T. A., Costa, R., Fagondes, S. C., John, Â. B., Jardim, L. B., Vedolin, L., Raymundo, M. M., Dickson, P., Kakkis, E., et al. (2008) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32294 · Cited by 136
Active‐site‐specific chaperone therapy for Fabry disease
Fan, J., & Ishii, S. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.06041.x · Cited by 131
Mu, T., Fowler, D. M., & Kelly, J. W. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060026 · Cited by 130
Parenti, G., Zuppaldi, A., Pittis, M. G., Tuzzi, M. R., Annunziata, I., Meroni, G., Porto, C., Donaudy, F., Rossi, B., Rossi, M., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300074 · Cited by 121
Self-citationGrubb, J. H., Vogler, C. A., Levy, B. K., Galvin, N. J., Tan, Y., & Sly, W. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712147105 · Cited by 117
Schueler, U., Kolter, T., Kaneski, C. R., Zirzow, G. C., Sandhoff, K., & Brady, R. O. (2004) · Journal of Inherited Metabolic Disease · doi:10.1023/b:boli.0000042959.44318.7c · Cited by 111
Okumiya, T., Kroos, M. A., de Vliet, L. V., Takeuchi, H., van der Ploeg, A. T., & Reuser, A. J. J. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.09.010 · Cited by 106
Pharmacologic chaperoning as a strategy to treat Gaucher disease
Yu, Z., Sawkar, A. R., & Kelly, J. W. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.06042.x · Cited by 105
Treiber, A., Morand, O. H., & Clozel, M. (2007) · Xenobiotica · doi:10.1080/00498250601094543 · Cited by 101
Limitations of enzyme replacement therapy: Current and future
Wraith, J. E. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0239-6 · Cited by 101
Hematopoietic Cell Therapy for Metabolic Disease
Orchard, P. J., Blazar, B. R., Wagner, J. E., Charnas, L. R., Krivit, W. A., & Tolar, J. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2007.04.054 · Cited by 100
Cardone, M., Porto, C., Tarallo, A., Vicinanza, M., Rossi, B., Polishchuk, E., Donaudy, F., Andria, G., Matteis, M. A. D., & Parenti, G. (2008) · PathoGenetics · doi:10.1186/1755-8417-1-6 · Cited by 100
Self-citationChemical and Biological Folding Contribute to Temperature‐Sensitive ΔF508 CFTR Trafficking
Wang, X., Koulov, A. V., Kellner, W. A., Riordan, J. R., & Balch, W. E. (2008) · Traffic · doi:10.1111/j.1600-0854.2008.00806.x · Cited by 91
Isofagomine Induced Stabilization of Glucocerebrosidase
Kornhaber, G. J., Tropak, M. B., Maegawa, G. H. B., Tuske, S. J., Coales, S. J., Mahuran, D. J., & Hamuro, Y. (2008) · ChemBioChem · doi:10.1002/cbic.200800249 · Cited by 90
Lysosomal storage diseases: Natural history and ethical and economic aspects
Beutler, E. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.01.010 · Cited by 88
Structural and mechanistic insight into the basis of mucopolysaccharidosis IIIB
Ficko‐Blean, E., Stubbs, K. A., Nemirovsky, O., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711491105 · Cited by 88
Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis
Elliot-Smith, E., Speak, A. O., Lloyd‐Evans, E., Smith, D. A., van der Spoel, A. C., Jeyakumar, M., Butters, T. D., Dwek, R. A., d’Azzo, A., & Platt, F. M. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.02.005 · Cited by 84
Andersson-Hall, U. K., Smith, D. A., Jeyakumar, M., Butters, T. D., Cortina‐Borja, M., Dwek, R. A., & Platt, F. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.012 · Cited by 81
Tropak, M. B., Kornhaber, G. J., Rigat, B. A., Maegawa, G. H. B., Buttner, J. D., Blanchard, J., Murphy, C., Tuske, S. J., Coales, S. J., Hamuro, Y., et al. (2008) · ChemBioChem · doi:10.1002/cbic.200800304 · Cited by 81
Bonapace, G., Waheed, A., Shah, G. N., & Sly, W. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404764101 · Cited by 73
Derrick‐Roberts, A. L. K., Rees, M., Klebe, S., Fletcher, J. M., & Byers, S. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.06.016 · Cited by 72
Wang, G., Reinkensmeier, G., Zhang, S., Zhou, J., Zhang, L., Zhang, L., Butters, T. D., & Ye, X. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801506m · Cited by 65
Chemical chaperone therapy: clinical effect in murine GM1‐gangliosidosis
Suzuki, Y., Ichinomiya, S., Kurosawa, M., Ohkubo, M., Watanabe, H., Iwasaki, H., Matsuda, J., Noguchi, Y., Takimoto, K., Itoh, M., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21284 · Cited by 60
Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase
Shen, J.-S., Edwards, N. J., Hong, Y. B., & Murray, G. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.02.125 · Cited by 59
Nagai, Y., & Popiel, H. A. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404164 · Cited by 57
Targeting of the CNS in MPS-IH Using a Nonviral Transferrin-α-l-iduronidase Fusion Gene Product
Osborn, M. J., McElmurry, R. T., Peacock, B. N., Tolar, J., & Blazar, B. R. (2008) · Molecular Therapy · doi:10.1038/mt.2008.119 · Cited by 57
Xu, Y.-H., Ponce, E., Sun, Y., Leonova, T., Bove, K. E., Witte, D. P., & Grabowski, G. A. (1996) · Pediatric Research · doi:10.1203/00006450-199602000-00021 · Cited by 57
Douillard‐Guilloux, G., Raben, N., Takikita, S., Batista, L., Caillaud, C., & Richard, E. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn290 · Cited by 51
Urban, D. J., Zheng, W., Göker-Alpan, Ö., Jadhav, A., LaMarca, M. E., Inglese, J., Sidransky, E., & Austin, C. P. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708786734244 · Cited by 46
Cox-Brinkman, J., Breemen, M., Maldegem, B. T., Bour, L., Donker, W., Hollak, C., Wijburg, F., & Aerts, J. M. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0873-2 · Cited by 42
Sugawara, K., Tajima, Y., Kawashima, I., Tsukimura, T., Saito, S., Ohno, K., Iwamoto, K., Kobayashi, T., Itoh, K., & Sakuraba, H. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.12.017 · Cited by 41
Yoshimizu, M., Tajima, Y., Matsuzawa, F., Aikawa, S., Iwamoto, K., Kobayashi, T., Edmunds, T., Fujishima, K., Tsuji, D., Itoh, K., et al. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.02.014 · Cited by 37
Chaperone-Like Antibodies in Neurodegenerative Tauopathies: Implication for Immunotherapy
Kontseková, E., Ivanovova, N. P., Handzusova, M., & Novák, M. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9355-9 · Cited by 21
Cited by
A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments
Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020441 · Cited by 868
Emerging principles for the therapeutic exploitation of glycosylation
Dalziel, M., Crispin, M., Scanlan, C. N., Zitzmann, N., & Dwek, R. A. (2014) · Science · doi:10.1126/science.1235681 · Cited by 447
Lysosomal storage diseases: from pathophysiology to therapy
Parenti, G., Andria, G., & Ballabio, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-122313-085916 · Cited by 404
Self-citationStructure of human lysosomal acid α-glucosidase–a guide for the treatment of Pompe disease
Roig-Zamboni, V., Cobucci-Ponzano, B., Iacono, R., Ferrara, M. C., Germany, S., Bourne, Y., Parenti, G., Moracci, M., & Sulzenbacher, G. (2017) · Nature Communications · doi:10.1038/s41467-017-01263-3 · Cited by 317
Self-citationUbiquitin and membrane protein turnover: from cradle to grave
MacGurn, J. A., Hsu, P.-C., & Emr, S. D. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060210-093619 · Cited by 287
Metadata
- Authors
- Parenti, G.
- Venue
- EMBO Molecular Medicine
- Published
- 2009-08
- Volume
- 1
- Issue
- 5
- Pages
- 268-279
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2116313758
- Cited by
- 273
- References
- 67
- FWCI
- 16.93
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.